Gastrointestinal Health News and Research

Latest Gastrointestinal Health News and Research

Mayo Clinic, University of Illinois announce strategic alliance for technology-based health care

Mayo Clinic and the University of Illinois at Urbana-Champaign are announcing a strategic alliance designed to promote a broad spectrum of collaborative research, development of new technologies and clinical tools, and design and implementation of novel education programs. Both parties recently signed an agreement establishing the formal relationship.

23 Jun 2010

Benioff family gifts $100 million for construction of new UCSF Children's Hospital at Mission Bay

Salesforce.com chairman and CEO Marc Benioff and his family have given a $100 million private gift to help fund the construction of the new UCSF Children's Hospital at the UCSF Mission Bay campus near downtown San Francisco. The gift is both the largest gift the donors have ever made and the largest gift ever granted specifically to the UCSF Children's Hospital.

22 Jun 2010

Protea Biosciences, Mayoly-Spindler commence Phase I/IIA human clinical trial for new recombinant Lipase

Protea Biosciences, Inc., a leading developer of new technology for pharmaceutical research, announced today that the company, in partnership with Mayoly-Spindler, a European pharmaceutical company, has commenced a Phase I/IIA human clinical trial for a new recombinant Lipase.

22 Jun 2010

Sun Pharma settles litigation with Orion over generic Stalevo, Comtan ANDAs

Sun Pharmaceutical Industries Ltd. announced that together with its affiliates ("Sun Pharma") it has executed a settlement agreement with Orion stipulating a dismissal of the lawsuits filed in the United States against Sun Pharma regarding submission of Abbreviated New Drug Applications (ANDAs) for generic versions of Stalevo® and Comtan® tablets.

22 Jun 2010

Surveillance colonoscopy is effective when targeted to high-risk patients: Study

Surveillance colonoscopy is effective and cost-effective when targeted to high-risk patients, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association Institute. However, overuse of surveillance colonoscopy could be excessively costly or even harmful.

22 Jun 2010

Lexicon presents LX4211 Phase 2a clinical trial results for type 2 diabetes mellitus at ENDO 2010

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, presented clinical data and analysis from its Phase 2a clinical trial of LX4211 for patients with type 2 diabetes mellitus at ENDO 2010 today. The results reported today included newly-obtained data showing a trend of increased total GLP-1 in both LX4211 treatment arms relative to placebo as measured in a post-trial analysis of blood samples.

22 Jun 2010

Ferring announces availability of LYSTEDA for cyclic heavy menstrual bleeding in U.S.

Ferring Pharmaceuticals Inc. announced today the U.S. commercial availability of LYSTEDA™ (tranexamic acid) tablets, the only non-hormonal and non-surgical therapy indicated specifically for the treatment of women with cyclic heavy menstrual bleeding (HMB). In clinical studies, LYSTEDA significantly reduced menstrual blood loss (MBL) over three and six cycles of use with the reduction seen as early as the first cycle of use.

21 Jun 2010

Essen BioScience, Nycomed partner to develop modulators of voltage-gated ion channels

Essen BioScience Inc. - a specialty provider of cell-based assay solutions and contract research services - and Nycomed - a privately owned global pharmaceutical company headquartered in Zurich, Switzerland - are pleased to announce a joint discovery agreement to identify novel small molecule ion channel modulators as pain therapeutics.

From Sartorius 21 Jun 2010

Preliminary top-line results from Hematide Phase 3 program for anemia in chronic renal failure patients

Affymax, Inc. and Takeda Global Research & Development Center, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced preliminary top-line results from the Phase 3 clinical program for the investigational drug, Hematide™/peginesatide, for the treatment of anemia in chronic renal failure patients.

21 Jun 2010

Arterial reconstruction in adult-to-adult LDLT has high risk of thrombosis: Study

Hepatic artery thrombosis, which is the most common vascular complication after living donor liver transplantation, can result in graft loss and devastating consequences. Surgical techniques are suggested to an important factor in causing HAT. Despite improvements in surgical techniques, arterial reconstruction in LDLT has a high risk of thrombosis.

21 Jun 2010

USFDA approves Sun Pharma's generic Xanax ANDA

Sun Pharma announced that USFDA has granted an approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Xanax®, alprazolam tablets.

18 Jun 2010

Pelvic extraperitoneal IMT with malignant transformation in 14-year-old

Inflammatory myofibroblastic tumor (IMT) is an uncommon benign neoplasm with locally aggressive behavior but malignant change is rare. Such a rare tumor occurring in a 14-year-old patient with clinical presentations of abdominal pain and body weight loss was seldom described before.

18 Jun 2010

Blueberry consumption is beneficial for hepatic diseases: Study

Conventional drugs used in the treatment of liver diseases inevitably have side effects. An increasing number of natural substances have been studied to explore if they have protective effects on the liver. Blueberries have unique effects on human retinal, brain and tumor cells, but reports about the effects of blueberries on liver diseases are lacking.

18 Jun 2010

Neonatal diarrhea may lead to life threatening dehydration and malnutrition: Research

Diarrhea represents a major condition responsible for pediatric mortality worldwide. The onset of neonatal diarrhea may rapidly lead to life threatening dehydration and malnutrition. Clinical and epidemiologic studies defining severity and etiology are needed in order to improve diagnostic and therapeutic approaches for the management of neonatal diarrhea.

18 Jun 2010

Study evaluates effect of Viusid on oxidative stress, cytokine parameters in patients with CHC

The pathogenesis of chronic hepatitis C is associated with severe oxidative stress and non-selective immunological disturbance that lead to necroinflammation and the progression of fibrosis. Several trials have suggested that antioxidant and immunostimulant therapies may have a beneficial effect. Two previous clinical studies have reported that the Viusid related effect on histologic features, especially fibrosis, appears to be associated with antioxidant and/or immunomodulatory properties.

18 Jun 2010

Neurocrine Biosciences, Boehringer Ingelheim collaborate to develop GPR119 agonists for Type II diabetes

Neurocrine Biosciences, Inc. announced today that they have established a worldwide collaboration with Boehringer Ingelheim to research and develop small molecule GPR119 agonists for the treatment of Type II diabetes and other indications. The companies will work jointly to identify and advance candidates into pre-clinical development. Boehringer Ingelheim is responsible for the global development and commercialization of potential GPR119 agonist products.

17 Jun 2010

USFDA approves Sun Pharma's generic Keppra Injection ANDA

Sun Pharma announced that USFDA has granted an approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Keppra® Injection, levetiracetam injection.

17 Jun 2010

Abbott, Neurocrine enter collaboration to develop, commercialize elagolix for endometriosis-related pain

Abbott and Neurocrine Biosciences, Inc. today announced that they have entered into a collaboration agreement to develop and commercialize elagolix for the treatment of endometriosis-related pain. Elagolix is a novel, first-in-class oral gonadotropin-releasing hormone (GnRH) antagonist, which has recently completed a phase IIb study in endometriosis. In addition to endometriosis, elagolix will be evaluated for the treatment of uterine fibroids.

16 Jun 2010

Norgine to develop and commercialize Tranzyme's ulimorelin ghrelin agonist

Tranzyme Pharma, a clinical-stage biopharmaceutical company, and Norgine B.V., a European specialty pharmaceutical company, announced today that they have entered into a licensing agreement that provides Norgine with the exclusive rights to develop and commercialize Tranzyme's novel ghrelin agonist, ulimorelin (TZP-101), in Europe, Australia, New Zealand, the Middle East, South Africa and North Africa. Ulimorelin is entering Phase 3 development for the treatment of gastrointestinal dysmotility conditions in acute care settings.

16 Jun 2010

Bayer sues Teva, Barr in connection with oral contraceptive Gianvi

Today, Bayer HealthCare Pharmaceuticals Inc. and Bayer Schering Pharma AG sued Teva Pharmaceuticals USA, Inc., Barr Pharmaceuticals LLC, and Barr Laboratories, Inc. in the Northern District of Illinois (Chicago) for false advertising and patent infringement in connection with Teva's generic oral contraceptive, Gianvi™. Teva's product is sold as a generic version of Bayer HealthCare's leading oral contraceptive YAZ®.

16 Jun 2010

Gastrointestinal Health News and Research

Latest Gastrointestinal Health News and Research

Mayo Clinic, University of Illinois announce strategic alliance for technology-based health care

Benioff family gifts $100 million for construction of new UCSF Children's Hospital at Mission Bay

Protea Biosciences, Mayoly-Spindler commence Phase I/IIA human clinical trial for new recombinant Lipase

Sun Pharma settles litigation with Orion over generic Stalevo, Comtan ANDAs

Surveillance colonoscopy is effective when targeted to high-risk patients: Study

Lexicon presents LX4211 Phase 2a clinical trial results for type 2 diabetes mellitus at ENDO 2010

Ferring announces availability of LYSTEDA for cyclic heavy menstrual bleeding in U.S.

Essen BioScience, Nycomed partner to develop modulators of voltage-gated ion channels

Preliminary top-line results from Hematide Phase 3 program for anemia in chronic renal failure patients

Arterial reconstruction in adult-to-adult LDLT has high risk of thrombosis: Study

USFDA approves Sun Pharma's generic Xanax ANDA

Pelvic extraperitoneal IMT with malignant transformation in 14-year-old

Blueberry consumption is beneficial for hepatic diseases: Study

Neonatal diarrhea may lead to life threatening dehydration and malnutrition: Research

Study evaluates effect of Viusid on oxidative stress, cytokine parameters in patients with CHC

Neurocrine Biosciences, Boehringer Ingelheim collaborate to develop GPR119 agonists for Type II diabetes

USFDA approves Sun Pharma's generic Keppra Injection ANDA

Abbott, Neurocrine enter collaboration to develop, commercialize elagolix for endometriosis-related pain

Norgine to develop and commercialize Tranzyme's ulimorelin ghrelin agonist

Bayer sues Teva, Barr in connection with oral contraceptive Gianvi

Microbiology eBook

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Gastrointestinal Health News and Research

Latest Gastrointestinal Health News and Research

Microbiology eBook

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Newsletters you may be interested in